Company news
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) news
Catalyst Pharmaceuticals, Inc. news releases on 6ix. Latest, Jul 24, 2024: Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply…
Press releases — page 2
Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in Canada
July 23, 2024
Catalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024
July 21, 2024
Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®
May 29, 2024
Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024
May 27, 2024
Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update
May 7, 2024
Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024
April 30, 2024
Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024
April 21, 2024
Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day
March 27, 2024
Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium
March 26, 2024
Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)
March 12, 2024
Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference
March 4, 2024
Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 27, 2024
Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE
February 26, 2024
Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology
February 20, 2024
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
February 13, 2024
Catalyst Pharmaceuticals, Inc. Announces Closing of Public Offering
January 8, 2024
Catalyst Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
January 4, 2024
Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
January 3, 2024
Catalyst Pharmaceuticals Announces FIRDAPSE® New Drug Application Submitted in Japan by Partner DyDo Pharma
December 17, 2023
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2024 List of America's Most Successful Small-Cap Companies
December 4, 2023
Catalyst Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer and Other Executive Promotions
December 3, 2023
Catalyst Pharmaceuticals To Participate in Piper Sandler 35th Annual Healthcare Conference
November 15, 2023
Catalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results and Corporate Update
November 7, 2023
Catalyst Pharmaceuticals Receives Two New U.S. Patent Allowances For FIRDAPSE®
November 1, 2023
Catalyst Pharmaceuticals Partners with Sofie's Journey to Bring Focus on Epilepsy at the 11th Annual Epilepsy Awareness and Education Expo
October 29, 2023
Catalyst Pharmaceuticals Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals
October 25, 2023
Catalyst Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 8, 2023
October 22, 2023
Catalyst Pharmaceuticals Appoints Richard J. Daly as Chief Executive Officer
October 18, 2023
Catalyst Pharmaceuticals Announces FDA Acceptance of the Supplemental New Drug Application for FIRDAPSE®
October 12, 2023
Catalyst Pharmaceuticals to Participate at the 2023 Cantor Global Healthcare Conference
September 17, 2023
Catalyst Pharmaceuticals Announces Abstract on Lambert Eaton Myasthenic Syndrome (LEMS) to be Presented at the Upcoming IASLC 2023 World Conference of Lung Cancer
August 15, 2023
Catalyst Pharmaceuticals Announces Multiple Abstracts on FYCOMPA® (Perampanel) from Eisai Co, Ltd., to be Presented at the 35th International Epilepsy Congress
August 13, 2023
Catalyst Pharmaceuticals Reports Strong Second Quarter 2023 Financial Results and Provides Corporate Update
August 8, 2023
Patrick J. McEnany Announces Intention to Retire as CEO of Catalyst Pharmaceuticals by Year-End
July 24, 2023
Catalyst Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 9, 2023
July 23, 2023
Catalyst Pharmaceuticals Acquires Exclusive North American License For Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
July 18, 2023
Catalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
June 19, 2023
Catalyst Pharmaceuticals Reports Positive Momentum in Second Quarter 2023
May 31, 2023
Catalyst Pharmaceuticals Appoints Tamar Thompson to its Board of Directors
May 29, 2023
Catalyst Pharmaceuticals Reports Record First Quarter 2023 Results, Achieving 98% Total Revenue Growth Year-over-Year
May 9, 2023
Catalyst Pharmaceuticals Advances sNDA Submission Plans To Increase Indicated Maximum Dose For FIRDAPSE® From 80 mg Per Day To 100 mg Per Day
May 8, 2023
Catalyst Pharmaceuticals Announces Release of Inaugural ESG Report
April 30, 2023
Catalyst Pharmaceuticals to Report First Quarter 2023 Financial Results on May 10, 2023
April 23, 2023
Catalyst Pharmaceuticals Announces Third-Party Abstracts on FYCOMPA® (Perampanel) to be Presented at the Upcoming American Academy of Neurology 2023 Annual Meeting
April 19, 2023
Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 14, 2023
Catalyst Pharmaceuticals Announces a Recent Third-Party Publication in Peer-Reviewed Journal Epilepsia Showing Perampanel (FYCOMPA®) Demonstrated High Efficacy in Patients with Rare Genetic Epilepsies
March 7, 2023
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on March 15, 2023
February 28, 2023
Catalyst Pharmaceuticals to Ring the Nasdaq Closing Bell in Honor of International Rare Disease Day
February 21, 2023
Catalyst Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2022 Total Revenues and Provides Full Year 2023 Revenue Guidance
February 6, 2023
Catalyst Pharmaceuticals Completes the Acquisition of U.S. Rights to FYCOMPA® (Perampanel) CIII
January 24, 2023